BCI Value Chain: Tech-and-Commercialization 'Resonance', and the Cost of Three Routes

Bar chart comparing clinical/registration timelines of three BCI routes — Timelines differ sharply by route: invasive 5–8 years, semi-invasive ~5, non-invasive 2–3 (Class II/III). Figures are research-level orders of magnitude.

In short: A BCI is a direct link between brain electrical activity and external devices — acquisition, front-end hardware, decoding, effector/feedback — classed by implantation as invasive, semi-invasive, non-invasive and endovascular (invasive/semi-invasive are mostly Class III). The field benefits from China's 15th-Five-Year priority, insurance coding and device standards, plus Neuralink volume expectations and domestic clinical progress. On products: invasive remains in trials; non-invasive is partly on market (clinical rehab systems, consumer sleep aids). Competition centers on electrodes, chips, algorithms; near-term commercialization is non-invasive, while the long-term core is the (semi-)invasive 'flexible electrode + high-throughput low-power chip', multi-center trials and standards.

Three routes: timeline, cost and samples

From R&D difficulty to safety and use case, the routes differ sharply (the table shows brokerage-research orders of magnitude, not product specs):

Type	Clinical/registration timeline	Per-case clinical cost	Typical R&D investment
Invasive	5–8 yrs (animal→EFS→pivotal→PMA/NMPA)	RMB100k–300k/case ($40k–100k+ intl.)	RMB150m–several hundred m
Semi-invasive	~5 yrs (still Class III)	near or below invasive	~RMB100m scale
Non-invasive	2–3 yrs (Class II/III); consumer shorter	—	RMB millions–tens of m

How to read the chain

Upstream: EEG sensors, core chips — benefiting from device volume;
Midstream: firms with core patents and clinical resources — invasive benchmarking global, non-invasive leaders with fast deployment;
Downstream: rehab and industrial-control scenarios with closed commercial loops; watch 'AI+BCI' and 'robot+BCI' ecosystems.

The BIO angle

This value-chain analysis names 'flexible electrode + encapsulation' as the long-term barrier for (semi-)invasive BCI. Flexible-electrode insulation, device encapsulation and reduced foreign-body response all rely on implant-grade medical silicone/polymers — exactly BIO's upstream-materials layer.

FAQ

What stage is BCI at now?

At the inflection from technical breakthrough to commercialization: non-invasive partly on market, invasive still in trials; driven by both policy and capital.

How different are the clinical timelines?

Invasive 5–8 years, semi-invasive ~5, non-invasive 2–3 (Class II/III; consumer/research shorter).

Why are electrodes and encapsulation the barrier?

Long-term (semi-)invasive implants require flexible electrodes plus reliable encapsulation — stable signal and low foreign-body response — a combined materials-and-engineering barrier.

BCI value chain: the 'resonance' of tech and commercialization

Three routes: timeline, cost and samples

How to read the chain

The BIO angle

FAQ

Related reading

Building in China's medical-device market?